GLUE
Monte Rosa Therapeutics Inc
9.90$
-3.9%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -0.14 | -0.52 | -1.28 | -1.96 | -0.85 | 0.57 | -0.35 | |
| 0.00 | 0.01 | 0.05 | 0.08 | 0.12 | 0.11 | 0.13 | |
| 0.00 | 0.01 | 0.11 | 0.25 | 0.32 | 0.25 | 0.29 | |
| -0.08 | 0.18 | 0.11 | 0.24 | – | – | – | |
| 0.04 | 0.10 | 0.14 | -0.05 | 1.41 | 1.24 | -0.14 | |
| 0.03 | 0.08 | 0.21 | 0.27 | 0.37 | 0.05 | 0.07 | |
| -0.03 | -0.08 | -0.21 | -4.64 | 1.73 | -0.60 | -1.55 | |
| 0.00 | -0.01 | 8.11 | 0.44 | 0.00 | -0.01 | -0.01 | |
| 0.20 | – | – | – | – | – | – | |
| 0.34 | 1.36 | 8.11 | 0.43 | 0.53 | 1.34 | 0.46 | |
| 0.17 | 0.74 | 6.63 | -6.17 | 1.41 | 1.30 | -1.44 | |
| -0.17 | -0.60 | -1.48 | -2.23 | -1.22 | 0.51 | -0.42 |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.